PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A growth above 1.5x GNPX's 52.68%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
547.73%
Operating expenses growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
547.73%
Total costs growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
3.95%
Interest expense change of 3.95% while GNPX maintains costs. Bruce Berkowitz would investigate control.
-96.03%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-2633.53%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses growth above 1.5x GNPX's 46.73%. Michael Burry would check for concerning trends.
-429.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Tax expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
-263.73%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
-197.18%
Diluted EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
22.83%
Share count reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.
22.83%
Diluted share reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.